Pro-Dex (PDEX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for November 20, 2025, with voting available online or in person.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of seven directors, with nominees listed for shareholder approval.
Ratification of Baker Tilly US, LLP as independent auditor for fiscal year ending June 30, 2026.
Advisory vote to approve executive compensation for Named Executive Officers.
Advisory vote on the frequency of future say-on-pay votes.
Proposal to amend and extend the 2016 Equity Incentive Plan for an additional ten years.
Board of directors and corporate governance
Board recommends all director nominees and proposals for shareholder approval.
Proxies authorized to vote on additional business as may arise at the meeting.
Latest events from Pro-Dex
- Strong sales, new products, and investment gains boosted earnings and cash flow.PDEX
Q2 202629 Jan 2026 - Shareholders to vote on director elections, auditor, executive pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Shareholders to vote on board elections, auditor ratification, and executive pay amid record growth.PDEX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay vote set for November 21, 2024.PDEX
Proxy Filing1 Dec 2025 - Revenue and net income surged on strong device sales and investment gains, but margin fell.PDEX
Q1 202630 Oct 2025 - Revenue and profit surged on orthopedic product shipments, but inventory controls remain a risk.PDEX
Q2 202516 Oct 2025 - Revenue up 24% and net income quadrupled in fiscal 2025, with strong outlook for 2026.PDEX
Q4 20254 Sep 2025 - Net income rebounded to $2.5M on 25% sales growth and improved gross margin.PDEX
Q1 202513 Jun 2025 - Sales and operating income rose sharply in 2024, but net income dropped on investment losses.PDEX
Q4 202413 Jun 2025